A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler

Boehringer Ingelheim

Status

Completed

Conditions

Pulmonary Disease, Chronic Obstructive

Treatments

Drug: Spiolto® Respimat®

Study type

Observational

Funder types

Industry

Identifiers

NCT03663569

1237-0072

Details and patient eligibility

About

Open-label observational study which includes COPD patients that are receiving treatment with Spiolto® Respimat® for approximately 6 weeks, which is the average time between two medical consultations.

Enrollment

4,819 patients

Sex

All

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Written informed consent prior to participation
Female and male patients ≥40 years of age
Patients diagnosed with COPD and based upon the investigator's decision requiring a new prescription of Spiolto Respimat® (combination of two long-acting bronchodilators) according to Spiolto® Respimat® SmPC, GOLD COPD Strategy Document 2018 (GOLD COPD groups B to D) and local COPD guidelines

Exclusion criteria

Patients with contraindications according to Spiolto® Respimat® SmPC
Patients already on a LABA/LAMA combination (free and fixed dose) in the last 6 weeks before study entry
Patients continuing LABA/ICS treatment should not be additionally treated with Spiolto® Respimat® in order to avoid a double dosing of long-acting beta-agonists
Pregnancy and lactation
Current participation in any clinical trial or any other non-interventional study of a drug or device.